Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Isabel Grau 0034610286915
trialmanager@sogug.es


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
Back

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Recruiting

Open to: ALL

Age: 18.0 - N/A

London London Lancaster Sheffield London

Medical Conditions

Urinary Bladder Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2023 Mar 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Patients will receive treatment with erdafitinib alone (cohort 1)

Intervention Arm Group : Erdafitinib (ERDA) monotherapy;

Intervention Type : DRUG
Intervention Description : Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)

Intervention Arm Group : Erdafitinib (ERDA) and Cetrelimab (CET) combination;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Royal Marsden NHS Foundation Trust
    London
    SW3 6JJ
  • Charing Cross Hospital
    London
  • University Hospitals of Morecambe Bay NHS Foundation Trust
    Lancaster
    LA1 4RP
  • Sheffield Teaching Hospitals NHS Foundation Trust
    Sheffield
    S10 2SJ
  • Barts Health NHS Trust
    London
    W6 8JA

Isabel Grau 0034610286915
trialmanager@sogug.es



The study is sponsored by Spanish Oncology Genito-Urinary Group and is in collaboration with Janssen-Cilag Ltd.; Pivotal S.L..



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06511648
Last updated 22 August 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top